Physician Views snap poll: AbbVie's Rinvoq approved for RA; how will prescribers use it?

AbbVie's Rinvoq (upadacitinib) has secured long-awaited US approval as the third JAK inhibitor to treat adults with moderate-to-severe rheumatoid arthritis.

Rinvoq is earmarked by AbbVie as a key sales growth driver that could play an important role compensating for declining Humira revenues; and possession of both drugs should prove strategically advantageous for the company. However, Rinvoq enters the market with some questions being asked of an association between JAK inhibitors and an increased risk of thrombosis.

With our latest Physician Views snap poll, we are asking US-based rheumatologists to assess their attitudes towards Rinvoq at launch…


Q. The FDA has approved Rinvoq (upadacitinib) - a once-daily oral JAK inhibitor - to treat adults with moderately-to-severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Rinvoq will launch in the US later this month with a list price of $59,000 a year.

How would you describe your awareness of this product and its clinical data?

Never heard of it

Know only the name

Know some basic information

Very familiar


Q. How do you intend to prescribe Rinvoq during the next 12 months?







Q. How do you intend to use Rinvoq versus other treatments in the JAK inhibitor class - Xeljanz (tofacitinib) and Olumiant (baricitinib) - during the next 12 months?

Much less


About the same


Much more


Q. In what line of therapy do you intend to prescribe Rinvoq most frequently during the next 12 months?

First-line (post-methotrexate, pre-1st biologic)

Second-line (post- 1st biologic)





Q. Rinvoq has been developed, and will be marketed, by AbbVie; the marketer of Humira (adalimumab). What impact will this have on your use of Rinvoq?

I will use Rinvoq much less

I will use Rinvoq less

No impact on my use of Rinvoq

I will use Rinvoq more

I will use Rinvoq much more


Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.